Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rosuvastatin Calcium

FDA-approved product (tablet, oral), marketed as Crestor, Ezallor Sprinkle, Rosuvastatin Calcium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Rosuvastatin Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atherosclerosis
  • Cardiovascular disease
  • Coronary artery disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia
  • Hyperlipoproteinemia type 3

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rosuvastatin Calcium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rosuvastatin Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

    NCT00585143 · start 2008-01

    Registered record
    Registry ID
    NCT00585143
    Conditions
    Dyslipidemia, Renal Insufficiency
    Interventions
    ABT-335; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-10
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia, Renal Insufficiency
    InterventionABT-335; Rosuvastatin
    PhasePhase 1
    Registry statusCompleted

  • Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )

    NCT00526708 · start 2007-05

    Registered record
    Registry ID
    NCT00526708
    Conditions
    Dyslipidemia; Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-05
    Completion
    2007-11
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia; Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

    NCT00688454 · start 2007-02

    Registered record
    Registry ID
    NCT00688454
    Conditions
    Hypercholesteremia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-02
    Completion
    2008-01
    Enrolment
    3,392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesteremia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • C-Reactive Protein (CRP) in Obese Diabetic Women

    NCT00262548 · start 2005-10

    Registered record
    Registry ID
    NCT00262548
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Rosuvastatin; improvement of lipid profile
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-10
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionRosuvastatin; improvement of lipid profile
    PhasePhase 4
    Registry statusCompleted

  • OLE Study to Evaluate Safety / Efficacy of ZD4522

    NCT00654303 · start 1999-08

    Registered record
    Registry ID
    NCT00654303
    Conditions
    Hypercholesterolaemia
    Interventions
    Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-08
    Completion
    2005-02
    Enrolment
    3,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolaemia
    InterventionRosuvastatin
    PhasePhase 3
    Registry statusCompleted